New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A V Approach
Drug Metabolism and Disposition · 2026
DOI: 10.1016/j.dmd.2026.100248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Xiaodong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, …. Hauptthemen laut MEDLINE: Lignans, Cyclooctanes, Polycyclic Compounds, Cytochrome P-450 CYP3A. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Interindividual variability in drug response stems largely from metabolic enzyme activity differences, with cytochrome P450 3A (CYP3A) being the predominant enzyme whose fluctuations critically impact exposure to narrow-therapeutic-index drugs (eg, tacrolimus) and anticancer agents. Current clinical probes such as midazolam (suboptimal hepatic uptake, sedation) and the erythromycin breath test (poor selectivity) remain inadequate. This study proposes deoxyschizandrin (DS), derived from Schisandra chinensis, as a novel in vivo CYP3A probe substrate. Using integrated rat in situ liver perfusion, whole-animal studies, physiologically based pharmacokinetic modeling, and proteomics, we demonstrated DS's advantageous properties: ideal biliary disposition (>80% hepatic accumulation, negligible parent/metabolite biliary excretion 5 × Km) for ∼20 minutes after a bolus dose of 25 mg/kg, enabling linear metabolite generation and apparent Vmax determination; and precise activity quantification (in vivo Vmax strongly correlated with rat hepatic CYP3A2 protein content, R2 = 0.89, P = .0047). Collectively, these findings demonstrate that DS enables accurate quantification of CYP3A activity through the Vmax approach, thereby providing a promising candidate for the development of a clinically viable in vivo CYP3A probe. SIGNIFICANCE STATEMENT: This study identifies deoxyschizandrin as a novel, safe, and liver-specific in vivo probe substrate for cytochrome P450 3A (CYP3A). It enables the quantitative determination of hepatic CYP3A maximum metabolic capacity through a bolus dosing protocol, offering a promising candidate for the development of a clinically viable in vivo CYP3A probe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China; Institute of Interdisciplinary…
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Pharmacy, Shanghai Yangsi Hospital, Shanghai, China. Electronic address: lyptjfll@163.com.
- Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China. Electronic address: wjj@dmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Hu, C., Wei, G., Chen, T., Tao, J., Wu, J., & Yang, L. (2026). New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A V Approach. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2026.100248
Vancouver
Li X, Hu C, Wei G, Chen T, Tao J, Wu J, et al. New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A V Approach. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2026.100248
BibTeX
@article{Li2026,
author = {Li, Xiaodong and Hu, Cong and Wei, Guilin and Chen, Tongyu and Tao, Jianfei and Wu, Jingjing and Yang, Ling},
title = {New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A V Approach},
journal = {Drug Metabolism and Disposition},
year = {2026},
doi = {10.1016/j.dmd.2026.100248}
}
EUVIMED